Lucid Diagnostics Inc LUCD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/10/24 EDT
0.95quote price arrow up+0.0056 (+0.593%)
Volume
815
Close
0.9444quote price arrow up+0.0147 (+1.5812%)
Volume
246,058
52 week range
0.63 - 1.85
Loading...
  • Open0.9908
  • Day High0.9999
  • Day Low0.92
  • Prev Close0.9297
  • 52 Week High1.85
  • 52 Week High Date06/05/23
  • 52 Week Low0.63
  • 52 Week Low Date04/25/24

Key Stats

  • Market Cap47.016M
  • Shares Out49.78M
  • 10 Day Average Volume0.35M
  • Dividend-
  • Dividend Yield-
  • Beta1.48
  • YTD % Change-33.02

KEY STATS

  • Open0.9908
  • Day High0.9999
  • Day Low0.92
  • Prev Close0.9297
  • 52 Week High1.85
  • 52 Week High Date06/05/23
  • 52 Week Low0.63
  • 52 Week Low Date04/25/24
  • Market Cap47.016M
  • Shares Out49.78M
  • 10 Day Average Volume0.35M
  • Dividend-
  • Dividend Yield-
  • Beta1.48
  • YTD % Change-33.02

RATIOS/PROFITABILITY

  • EPS (TTM)-1.26
  • P/E (TTM)-0.75
  • Fwd P/E (NTM)-0.94
  • EBITDA (TTM)-45.983M
  • ROE (TTM)-4,989.67%
  • Revenue (TTM)2.428M
  • Gross Margin (TTM)-146.21%
  • Net Margin (TTM)-2,169.11%
  • Debt To Equity (MRQ)-1,007.75%

EVENTS

  • Earnings Date05/13/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Lucid Diagnostics Inc

Related Video

No more price cuts planned at the moment, says Lucid CEO Peter Rawlinson
VIDEO4:2004:20
No more price cuts planned at the moment, says Lucid CEO Peter Rawlinson

Profile

MORE
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface...
Lishan Aklog M.D.
Chairman of the Board, Chief Executive Officer
Stanley Lapidus
Vice Chairman of the Board
Shaun O'Neil
President, Chief Operating Officer
Dennis Mcgrath
Chief Financial Officer, Company Secretary
Michael Gordon
General Counsel, Secretary
Address
360 Madison Avenue, 25Th Floor
New York, NY
10017
United States

Top Peers

SYMBOLLASTCHG%CHG
MLSS
Milestone Scientific Inc
0.6646-0.0144-2.1208%
NXGL
Nexgel Inc
2.20-0.03-1.48%
SINT
SINTX Technologies Inc
0.0399-0.0038-8.6957%
VANI
Vivani Medical Inc
1.81+0.09+5.23%
NBY
NovaBay Pharmaceuticals Inc
0.0804-0.0089-9.9664%